Back to School: How biopharma can reboot drug development. Access exclusive analysis here

GEM 231 hybrid chemistry antisense compound: Phase I data

In a 13-patient dose escalation trial, GEM

Read the full 78 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE